NASDAQ$RVPH
Reviva Pharmaceuticals Holdi · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reviva reported its financial results for the full year 2023, highlighting the successful completion of the RECOVER-1 Phase 3 trial and progress towards NDA submission.
Reviva Pharmaceuticals reported a net loss of $39.3 million for the year ended December 31, 2023, compared to a net loss of $28.3 million for the previous year. The company's cash and cash equivalents totaled $23.4 million as of December 31, 2023, compared to $18.5 million as of December 31, 2022. The company is targeting a potential NDA submission in Q3 2025.
- RECOVER-1 Phase 3 trial met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia.
- Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024; topline data expected Q2 2025.
- Topline data from 1-year open-label extension (OLE) trial expected Q4 2024.
- Preparation is underway to support a New Drug Application (NDA) submission for brilaroxazine in schizophrenia targeted for Q3 2025.
Headline financials
Revenue & EPS history
Reviva · Revenue · Quarterly
$0
Forward guidance
Reviva anticipates several milestones including the initiation of the RECOVER-2 trial, topline data from the OLE trial and RECOVER-2 trial, and a potential NDA submission for brilaroxazine.
Tailwinds
- Initiation of registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia expected in Q2 2024
- Topline data from 1-year open-label extension (OLE) trial expected Q4 2024
- Topline data from registrational Phase 3 RECOVER-2 trial expected Q2 2025
- Potential NDA submission for brilaroxazine in schizophrenia targeted for Q3 2025
- May initiate Phase 2a studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in 2024
Headwinds
- The company reported a net loss for the year ended December 31, 2023.
- Clinical trial expenses were understated in previously issued financial statements.
- Company must evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations
- Company must pursue partnership opportunities for the development of our pipeline
- Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected in 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+16.7%
Avg return
30 days after
39%
11 / 28 earnings
Positive
+15.8%
Q2 2025
Best reaction
-22.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +9.6% | +13.7% | +94.3% | |
| Q3 2025 | -7.3% | -7.9% | +23.0% | |
| Q2 2025 | +15.8% | +11.4% | -5.1% | |
| Q1 2025 | +4.9% | +31.6% | -8.1% | |
| Q4 2024 | +15.0% | +16.0% | +17.1% | |
| Q3 2024 | -9.6% | +0.8% | +108.8% | |
| Q1 2024 | +0.6% | -1.8% | -11.8% | |
| Q4 2023 | -9.8% | -18.2% | -53.7% | |
| Q3 2023 | -17.2% | -33.6% | -37.1% | |
| Q2 2023 | +3.4% | +0.0% | +28.8% | |
| Q1 2023 | +5.4% | -0.5% | -15.6% | |
| Q4 2022 | -10.1% | -5.2% | +47.0% | |
| Q3 2022 | -22.9% | -9.5% | -21.6% | |
| Q2 2022 | +2.8% | +4.9% | +208.5% | |
| Q1 2022 | +15.3% | +17.1% | -20.4% | |
| Q4 2021 | +0.0% | -3.3% | +21.1% | |
| Q3 2021 | -1.3% | -10.3% | -11.4% | |
| Q2 2021 | -6.0% | -4.9% | +18.3% | |
| Q1 2021 | -0.2% | +12.2% | -1.2% | |
| Q4 2020 | -22.3% | -22.6% | -46.5% | |
| Q3 2020 | -0.7% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | +0.1% | — | — | |
| Q4 2019 | +0.0% | — | — | |
| Q3 2019 | +0.0% | — | — | |
| Q2 2019 | +0.4% | — | — | |
| Q1 2018 | -0.1% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro